Decisions by the Health and Human Services Department’s 340B administrative dispute resolution panel settling drug pricing disagreements between manufacturers and providers can be reconsidered by the federal agency overseeing the program under a proposed rule issued by HHS on 29 November.
“HHS believes that there should be an opportunity for dissatisfied parties to seek reconsideration of the 340B ADR panel’s decision by” the HHS Health Resources and Services Administration, the proposal...